By VETTAPHARMA reporter: The U.S. Food and Drug Administration (FDA) has launched a new initiative aimed at boosting domestic pharmaceutical manufacturing by improving regulatory predictability and streamlining the assessment of new drug production facilities, the agency announced today.
Under the FDA PreCheck pilot program, the agency has begun accepting requests from companies to participate in the effort to strengthen the U.S. pharmaceutical supply chain. The PreCheck program is designed to help facilitate the construction of new manufacturing sites and reduce regulatory barriers for domestic production in advance of specific product submissions.
The agency said it will select an initial cohort of new pharmaceutical manufacturing facilities that align with national priorities, including the type of products to be manufactured, the phase of facility development, the timeline for producing pharmaceutical products for the U.S. market, and the use of innovative facility technologies. Facilities that plan to produce critical medications for the U.S. market may receive additional priority consideration.
Feedback from industry stakeholders played a key role in shaping the PreCheck program. Comments gathered during the “Onshoring Manufacturing of Drugs and Biological Products” public meeting on September 30, 2025, and through the Federal Register informed the program’s structure, particularly the emphasis on early engagement during facility development and streamlined documentation processes.
The PreCheck pilot will follow a two-phase approach:
Phase 1: Facility Readiness Phase — Selected manufacturers can engage with the FDA for early technical advice before facilities are operational, including pre-operational reviews and use of facility-specific Drug Master Files to support evaluations prior to formal application submissions.
Phase 2: Application Submission Phase — The FDA and program participants will engage in pre-submission meetings and inspections to resolve issues and help expedite assessments of manufacturing information in a drug application.
According to the FDA, the PreCheck activities are expected to begin in 2026 as part of an effort to enhance the resilience and competitiveness of the U.S. pharmaceutical manufacturing sector.
The program represents a strategic step by the FDA to facilitate domestic drug production and reduce reliance on overseas manufacturing — a shift aligned with broader public health and national security goals, the agency said.
As the U.S. FDA launches its PreCheck pilot to strengthen domestic pharmaceutical manufacturing, the move signals a shift toward regulatory predictability and onshoring. For India, the world’s largest supplier of generic medicines to the U.S., the initiative could reshape inspection timelines, investment decisions, and long-term export dynamics as Washington prioritizes resilient, home-grown drug supply chains.
Source credit:
- U.S. Food and Drug Administration. (2026, February 1). FDA launches PreCheck pilot program to strengthen domestic pharmaceutical manufacturing [Press announcement]. Click here
Disclaimer:
The contents published on this platform are intended solely for informational and educational purposes. Reports, summaries, and discussions related to clinical trials are based on publicly available data, press releases, scientific publications, and regulatory disclosures available at the time of reporting. The information provided does not constitute medical advice, diagnosis, treatment recommendations, or endorsement of any drug, therapy, or clinical outcome. Clinical trial data are subject to change as studies progress, and results discussed may be preliminary, incomplete, or not yet peer-reviewed. Readers are strongly encouraged to refer to the original clinical trial records, regulatory filings, peer-reviewed articles or related sources for complete, accurate, and up-to-date information. Healthcare professionals and patients should consult qualified medical professionals and relevant regulatory authorities before making any healthcare or treatment decisions. Images used on this platform are illustrative in nature and are intended for conceptual and representational purposes only. They may not depict actual products, facilities, individuals, or events. The platform and its contributors disclaim any liability for actions taken based on the information presented.
